PURPOSE: To evaluate the prognostic significance of the integrin cell adhesion molecule very late antigen-4 (VLA-4) in acute myeloid leukemia (AML). PATIENTS AND METHODS: We prospectively quantified VLA-4 expression in 216 patients enrolled onto COG-AAML03P1 by flow cytometry and correlated expression levels with disease characteristics and clinical outcome. RESULTS: VLA-4 mean fluorescence intensity (MFI) varied 35-fold (range, 30 to 1,110; median, 219.5). High VLA-4 expression (> median MFI), compared with low expression, was associated with younger age (7.1 v 12.1 years, respectively; P < .001), lower FLT3 internal tandem duplication prevalence (4% v 21%, respectively; P < .001), and higher likelihood of extramedullary disease (16% v 5%, respectively; P = .013). In low- and high-expression groups, rates of remission (89% v 80%, respectively; P = .137) and minimal residual disease (29% v 25%, respectively; P = .700) were similar. Patients with low VLA-4 expression, compared with high expression, had a higher relapse rate (RR; 44% +/- 10% v 24% +/- 9%, respectively; P = .011) and lower disease-free survival (DFS; 48% +/- 11% v 67% +/- 10%, respectively; P = .023) after 3 years. Multivariate analyses showed that low VLA-4 expression was an independent adverse prognostic factor for DFS (hazard ratio [HR] = 1.98; P = .038) and RR (HR = 2.77; P = .009). Subgroup analyses indicated that the prognostic role of VLA-4 expression was most prominent in patients with standard-risk AML, in whom low VLA-4 expression was associated with inferior DFS (34% +/- 16% v 69% +/- 14% for high expression; P = .011) and higher RR (61% +/- 16% v 26% +/- 14% for high expression; P = .009). A similar trend was seen in low-risk but not high-risk patients. CONCLUSION: High VLA-4 expression is associated with better clinical outcome in pediatric AML and is an independent predictor of relapse that may refine our abilities to stratify patients without identifiable cytogenetic or molecular risk factors.
PURPOSE: To evaluate the prognostic significance of the integrin cell adhesion molecule very late antigen-4 (VLA-4) in acute myeloid leukemia (AML). PATIENTS AND METHODS: We prospectively quantified VLA-4 expression in 216 patients enrolled onto COG-AAML03P1 by flow cytometry and correlated expression levels with disease characteristics and clinical outcome. RESULTS: VLA-4 mean fluorescence intensity (MFI) varied 35-fold (range, 30 to 1,110; median, 219.5). High VLA-4 expression (> median MFI), compared with low expression, was associated with younger age (7.1 v 12.1 years, respectively; P < .001), lower FLT3 internal tandem duplication prevalence (4% v 21%, respectively; P < .001), and higher likelihood of extramedullary disease (16% v 5%, respectively; P = .013). In low- and high-expression groups, rates of remission (89% v 80%, respectively; P = .137) and minimal residual disease (29% v 25%, respectively; P = .700) were similar. Patients with low VLA-4 expression, compared with high expression, had a higher relapse rate (RR; 44% +/- 10% v 24% +/- 9%, respectively; P = .011) and lower disease-free survival (DFS; 48% +/- 11% v 67% +/- 10%, respectively; P = .023) after 3 years. Multivariate analyses showed that low VLA-4 expression was an independent adverse prognostic factor for DFS (hazard ratio [HR] = 1.98; P = .038) and RR (HR = 2.77; P = .009). Subgroup analyses indicated that the prognostic role of VLA-4 expression was most prominent in patients with standard-risk AML, in whom low VLA-4 expression was associated with inferior DFS (34% +/- 16% v 69% +/- 14% for high expression; P = .011) and higher RR (61% +/- 16% v 26% +/- 14% for high expression; P = .009). A similar trend was seen in low-risk but not high-risk patients. CONCLUSION: High VLA-4 expression is associated with better clinical outcome in pediatric AML and is an independent predictor of relapse that may refine our abilities to stratify patients without identifiable cytogenetic or molecular risk factors.
Authors: Michael Stefanidakis; Katja Karjalainen; Diana E Jaalouk; Carl G Gahmberg; Susan O'Brien; Renata Pasqualini; Wadih Arap; Erkki Koivunen Journal: Blood Date: 2009-07-27 Impact factor: 22.113
Authors: Pamela S Becker; Kenneth J Kopecky; Adrianne N Wilks; Sylvia Chien; John M Harlan; Cheryl L Willman; Stephen H Petersdorf; Derek L Stirewalt; Thalia Papayannopoulou; Frederick R Appelbaum Journal: Blood Date: 2008-10-16 Impact factor: 22.113
Authors: Jessica A Pollard; Todd A Alonzo; Michael Loken; Robert B Gerbing; Phoenix A Ho; Irwin D Bernstein; Susana C Raimondi; Betsy Hirsch; Janet Franklin; Roland B Walter; Alan Gamis; Soheil Meshinchi Journal: Blood Date: 2012-02-29 Impact factor: 22.113
Authors: George S Laszlo; Todd A Alonzo; Chelsea J Gudgeon; Kimberly H Harrington; Robert B Gerbing; Yi-Cheng Wang; Rhonda E Ries; Susana C Raimondi; Betsy A Hirsch; Alan S Gamis; Soheil Meshinchi; Roland B Walter Journal: Clin Cancer Res Date: 2015-03-30 Impact factor: 12.531
Authors: Soheil Meshinchi; Jessica A Pollard; Katherine Tarlock; Todd A Alonzo; Yi-Cheng Wang; Robert B Gerbing; Rhonda Ries; Michael R Loken; Laura Pardo; Tiffany Hylkema; Jason Joaquin; Leela Sarukkai; Susana C Raimondi; Betsy Hirsch; Lillian Sung; Richard Aplenc; Irwin Bernstein; Alan S Gamis Journal: Clin Cancer Res Date: 2019-06-10 Impact factor: 12.531
Authors: Jessica A Pollard; Michael Loken; Robert B Gerbing; Susana C Raimondi; Betsy A Hirsch; Richard Aplenc; Irwin D Bernstein; Alan S Gamis; Todd A Alonzo; Soheil Meshinchi Journal: J Clin Oncol Date: 2016-01-19 Impact factor: 44.544
Authors: Roland B Walter; George S Laszlo; Todd A Alonzo; Robert B Gerbing; Shawn Levy; Matthew P Fitzgibbon; Chelsea J Gudgeon; Rhonda E Ries; Kimberly H Harrington; Susana C Raimondi; Betsy A Hirsch; Alan S Gamis; Martin W McIntosh; Soheil Meshinchi Journal: Am J Hematol Date: 2013-06-20 Impact factor: 10.047